Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at ELRIG Drug Discovery 2022 - Driving the Next Life Science Revolution

2022-09-23
|
Page View:

1.png

ELRIG Drug Discovery 2022 is only one week to go! Medicilon is excited to exhibit in the conference. Medicilon European Team will be waiting at Booth A5b. We are happy to meet you in person to discuss how our services and capabilities would support your current research needs and expedite your drug discovery and development programs. We look forward to seeing you soon and wish you safe trips!

Date: 4-5 OCTOBER 2022

Location: EXCEL, LONDON

Booth: A5b

About ELRIG Drug Discovery 2022

DRUG DISCOVERY 2022 ELRIG’s annual Drug Discovery meeting is Europe’s largest meeting for life sciences industry professionals. During this conference, ELRIG will celebrate its long history of hosting disruptive and innovative drug discovery technology developments, whilst exploring the next life science revolutions. Drug Discovery 2022 promises to provide a platform for the whole drug discovery community to meet at a free to attend, in-person event. ELRIG has partnered with; BPS, SLAS, and RSC to draw together an exciting and progressive 2-day event containing; cutting-edge advancements in screening, automation and high content imaging, and innovations in disease models, advances in cell and gene therapies, revolutions through partnerships, future perspectives in medicinal and green chemistry and finally creative thinking to deliver therapies to one of the most challenging diseases facing society; COPD.

Overcoming Challenges and New Directions in Medicinal Chemistry

Many key proteins and processes in human disease have been considered “undruggable”.  However, recent advances against targets such as the RNA spliceosome and KRAS G12C have started to re-define the concept of druggability and how we can deliver forefront medicines across a range of diseases.  In this session, we will celebrate some of the recent advances in this space, describing the impact of synthetic and medicinal chemistry in delivering agents against challenging diseases.  Importantly, the talks will share key lessons learnt, to assist future success against equally challenging targets and our panel of experienced medicinal chemists will discuss their own experiences, future directions and upcoming challenges

At Medicilon, chemistry and biology are ingrained in every project we undertake. Our medicinal chemistry team is capable of flexibly applying computer chemistry to assist compound design process. In the meantime, we apply advanced drug discovery technologies, including proteolysis-targeting chimera (PROTAC), DNA-encoded chemical library (DEL) and antibody drug conjugation (ADC).

Cell & Gene Therapy

Often grouped together, these two complementary disciplines of therapy have not only delivered clinical impact through the efforts of academics and biotechs, they have also become pillars of many pharmaceutical companies medicine pipelines. With approaches as diverse as in vivo expressed biologics, CRISPR-based therapeutic gene editing and allogeneic immune cell engineering, it is easy to overlook the commonalities between this wide range of medicine formats. This session will provide an update on advances in this increasingly mainstream area of drug discovery, as well as shine a light on some of the shared challenges academics, clinicians and industry scientists are working together to overcome”.

Medicilon has established a one-stop research platform for the preclinical R&D of Cell & Gene immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed multiple preclinical projects for clients worldwide.

Frontiers of Chemistry applied to Drug Discovery

Sustainability, innovation, new modalities, synthetic methodology, target validation; what impact do all of these have on drug discovery and how can we use the most recent advances to improve the medicines we make? In this track we will hear about recent advances in sustainable chemistry, new synthetic methodology and its impact on drug discovery.

Medicilon Drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. In terms of chemistry, it can undertake multi-dimensional business such as custom synthesis, compound library construction, SAR compound synthesis and screening, compound structure and biological activity optimization. The medicinal chemistry team deeply cross-integrates chemistry and biology into each project, and flexibly uses the powerful expertise of computational chemistry to aid the compound design process. At the same time, Medicilon extensively uses advanced drug discovery technology, including PROTAC targeted protein degradation technology, DEL DNA-encoded small molecule compound library screening technology, ADC antibody drug conjugation technology, etc. Medicilon efficiently promotes customers' drug research and development projects, controls costs, and improves quality!

Developments in Preclinical Models

Driven by increased disease insight as well as a renaissance in screening approaches such as Functional Genomics, understanding biology, as well as the behaviour of emerging drug targets and candidate medicines within a complex cellular environment is critical to modern research. Academics and industry scientists are increasingly turning to advanced preclinical models in order to identify and validate new biological hypotheses, as well as mitigate the risks of clinical efficacy- and safety-based attrition for new medicines. This session will highlight some of the most exciting preclinical model systems at the forefront of this wave of innovation”.

Keeping pace with industrial development and market demand, Medicilon’s Pharmacology and Pharmacodynamics Department boasts years of experience, and has established a complete animal model library based on verifications and practices for precise and efficient drug efficacy testing. The test subjects include non-human primates, dogs, rats/mice, rabbits, guinea pigs, and miniature pigs. Medicilon boasts nearly 300 tumor evaluation models. At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal antibody, double antibody, polyclonal antibody, etc.), siRNA, AAV.

Share:
Return
Relevant newsRelevant news